Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01968733 · ClinicalTrials.gov registry record · Phase 3

Efficacy and Safety Study of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia

A Phase 3 study, sponsored by Melinta Therapeutics.

Completed
Registry status
Phase 3
Development phase
863
Enrollment target

NCT01968733: Completed Phase 3 study, sponsored by Melinta Therapeutics.

NCT01968733 is a Phase 3 study that has completed, run by Melinta Therapeutics. The registered enrollment target is 863 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (12% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01968733, a Phase 3 study, has completed, sponsored by Melinta Therapeutics.

COMPLETED
Registry status
Phase 3
Development phase
863 participants
Enrollment target

Study Summary

This study will evaluate the safety and efficacy of an experimental antibiotic, solithromycin, in the treatment of adult patients with community-acquired pneumonia.

Primary Outcome

To determine noninferiority (NI) in early clinical response rate, in at least 2 of the following 4 cardinal symptoms: cough, shortness of breath, chest pain, and sputum production

Interventions

  • DRUG Moxifloxacin
  • DRUG Solithromycin

Trial Details

FieldValue
Enrollment Target 863 participants
Start Date 2013-11
Est. Completion 2015-09
Phase Phase 3
Melinta Therapeutics

31 total trials

What the finished NCT01968733 record still lists

NCT01968733 is an interventional study that assigns participants to a tested intervention. The registered 863 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (12% higher).

The record links to 0 conditions, and to 2 interventions - of which Moxifloxacin is the first listed.

NCT01968733 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01968733 about?

NCT01968733 is a clinical study titled "Efficacy and Safety Study of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia". This study will evaluate the safety and efficacy of an experimental antibiotic, solithromycin, in the treatment of adult patients with community-acquired pneumonia.

What is the current status of trial NCT01968733?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 863 participants. The study started on 2013-11. Estimated completion is 2015-09.

What interventions are being tested in trial NCT01968733?

The interventions under investigation include: Moxifloxacin (DRUG), Solithromycin (DRUG).

Who is sponsoring clinical trial NCT01968733?

This trial is sponsored by Melinta Therapeutics, which has 31 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01968733's enrollment target sits among peer trials

863 380th of 2000 higher than 1,621 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06256588 · 864 participants · Phase 3

    A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

  • NCT06527794 · 864 participants · NA

    Remote Hypertension Management for Black Patients

  • NCT05914116 · 862 participants · Phase 1

    A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

  • NCT05369052 · 865 participants · Phase 3

    Safety and Efficacy Study of Contezolid Acefosamil and Contezolid Compared to Linezolid Administered Intravenously and Orally to Adults With Moderate or Severe Diabetic Foot Infections (DFI)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01968733, the US trial registry maintained by the National Library of Medicine. NCT01968733 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.